Oxford BioMedica Extends Agreement With AstraZeneca for Covid-19 Vaccine Facility
01 Julio 2022 - 2:11AM
Noticias Dow Jones
By Michael Susin
Oxford BioMedica PLC said Friday that it has signed an extended
agreement with AstraZeneca UK Ltd. for the use of its facility to
produce AstraZeneca's Covid-19 vaccine.
The U.K. gene and cell therapy group said the new three-year
agreement makes the vaccines manufacturing facility Oxbox available
to AstraZeneca on an as-needed basis beyond 2022.
The deal represents an expansion of the original deal between
the two companies in September 2020, which was originally expected
to be complete in the last quarter of 2022, it added.
The company added that the company expects to recognize an
aggregate revenue of 30 million pounds ($36.5 million) in the
current financial year from AstraZeneca for the batches already
manufactured in the first half of 2022.
Write to Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
July 01, 2022 02:56 ET (06:56 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Astrazeneca (LSE:AZN)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024